Table 3 Univariable analysis of late recurrence
Late recurrence (n = 33) | Late non-recurrence (n = 159) | P | |
|---|---|---|---|
Age (years old) | 59.82 ± 12.88 | 61.70 ± 10.93 | 0.471 |
Weight(kg) | 73.18 ± 12.47 | 69.33 ± 11.90 | 0.095 |
Duration of atrial fibrillation (months) | 42.66 ± 49.39 | 48.44 ± 79.96 | 0.537 |
Male | 25(75.8%) | 116(73.0%) | 0.740 |
Female | 8(24.2%) | 43(27.0%) | |
Heart failure | 2(6.1%) | 19(11.9%) | 0.497 |
Hypertension | 12(36.4%) | 65(40.9%) | 0.630 |
Diabetes | 4(12.1%) | 32(20.1%) | 0.284 |
Coronary heart disease | 3(9.1%) | 21(13.2%) | 0.718 |
Stroke history | 5(15.2%) | 13(8.2%) | 0.356 |
Peripheral vascular disease | 7(21.2%) | 39(24.5%) | 0.685 |
CHA2DS2-VASc score | 1.88 ± 1.75 | 2.07 ± 1.70 | 0.468 |
LA diameter(mm) | 45.56 ± 5.35 | 45.56 ± 6.24 | 0.794 |
EF(%) | 61.66 ± 6.32 | 60.58 ± 9.08 | 0.881 |
NT-proBNP(pg/mL) | 696.32 ± 602.12 | 796.08 ± 757.23 | 0.575 |
Early relapse | 1(3.0%) | 22(13.8%) | 0.148 |
Success rate of conversion using ibutilide | 21(63.6%) | 94(59.1%) | 0.630 |
Failure rate of conversion using ibutilide | 12(36.4%) | 65(40.9%) |